On March 5, 2024 Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR-driven cancers, reported poster presentations at the 2024 American Association for Cancer Research (AACR) (Free AACR Whitepaper), taking place April 5-10, 2024, in San Diego, CA (Press release, Aadi Bioscience, MAR 5, 2024, View Source [SID1234640824]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

AACR poster presentation details are below:

Title: "Evaluation of nab-sirolimus in combination with fulvestrant or PI3K pathway inhibitors to overcome resistance in breast cancer cell lines"
Session Title: Reversal of Drug Resistance 2
Location: Poster Section 25, Board Number 6
Abstract Number: 7196
Date/Time: Wednesday Apr 10, 2024, 9:00 AM – 12:30 PM
Presenting Author: Shihe Hou, PhD

Title: "Correlation of nab-sirolimus tumor drug levels and improved tumor suppression in KRAS G12C non-small cell lung cancer xenografts treated with nab-sirolimus in combination with KRAS inhibitors"
Session Title: Targeting Kinase and ERK Pathways
Location: Poster Section 46, Board Number 3
Abstract Number: 6486
Date/Time: Tuesday Apr 9, 2024 1:30 PM – 5:00 PM
Presenting Author: Shihe Hou, PhD

More information can be found on the AACR (Free AACR Whitepaper) meeting website.